JP2011527667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527667A5 JP2011527667A5 JP2011513994A JP2011513994A JP2011527667A5 JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5 JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011513994 A JP2011513994 A JP 2011513994A JP 2011527667 A5 JP2011527667 A5 JP 2011527667A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- methoxy
- pyrimido
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- -1 phenyl cyclopropyl Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- XJDFPABNFMGUQZ-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CC=C1 XJDFPABNFMGUQZ-UHFFFAOYSA-N 0.000 claims 1
- TUQMYIJNTSGUGF-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CC=C1 TUQMYIJNTSGUGF-UHFFFAOYSA-N 0.000 claims 1
- PSUBGYPXALNCMG-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 PSUBGYPXALNCMG-UHFFFAOYSA-N 0.000 claims 1
- XSDGPZQANIZACZ-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 XSDGPZQANIZACZ-UHFFFAOYSA-N 0.000 claims 1
- PCPAXXKTKQUPHR-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 PCPAXXKTKQUPHR-UHFFFAOYSA-N 0.000 claims 1
- NGAFYUZTCNBCGI-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-phenylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3C=CC=CC=3)C2=N1 NGAFYUZTCNBCGI-UHFFFAOYSA-N 0.000 claims 1
- KVBACVCSBJSAER-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CS1 KVBACVCSBJSAER-UHFFFAOYSA-N 0.000 claims 1
- DGGHCJPFKMNPAU-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCC1=CC=CS1 DGGHCJPFKMNPAU-UHFFFAOYSA-N 0.000 claims 1
- JSFTXPUPTJTYTB-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 JSFTXPUPTJTYTB-UHFFFAOYSA-N 0.000 claims 1
- KMWJCCMWYIKRNP-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 KMWJCCMWYIKRNP-UHFFFAOYSA-N 0.000 claims 1
- MNHDFLRMCRZSOS-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(2-thiophen-2-ylethyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCC=3SC=CC=3)C2=N1 MNHDFLRMCRZSOS-UHFFFAOYSA-N 0.000 claims 1
- QIMBUKMFWMBEHR-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCCC1=CC=CC=C1 QIMBUKMFWMBEHR-UHFFFAOYSA-N 0.000 claims 1
- PHXLWWFFQDNSSE-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(oxan-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCOCC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2CCCC1=CC=CC=C1 PHXLWWFFQDNSSE-UHFFFAOYSA-N 0.000 claims 1
- DMMUXYAYHYDDLV-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 DMMUXYAYHYDDLV-UHFFFAOYSA-N 0.000 claims 1
- UXZZINQYOKUPEO-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 UXZZINQYOKUPEO-UHFFFAOYSA-N 0.000 claims 1
- XXIJBRADQSRHDK-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 XXIJBRADQSRHDK-UHFFFAOYSA-N 0.000 claims 1
- GHTYTXXJOCCCQB-UHFFFAOYSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-(3-phenylpropyl)-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2CCCC=3C=CC=CC=3)C2=N1 GHTYTXXJOCCCQB-UHFFFAOYSA-N 0.000 claims 1
- QREWJFAVPDUZPY-LADGPHEKSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1([C@@H]2C[C@H]2N2CC(F)(F)C(=O)N(C)C3=CN=C(N=C32)NC2=CC=C(C=C2OC)C(=O)NC2CCN(C)CC2)=CC=CC=C1 QREWJFAVPDUZPY-LADGPHEKSA-N 0.000 claims 1
- AVYWETQIOGLARX-FUHWJXTLSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 AVYWETQIOGLARX-FUHWJXTLSA-N 0.000 claims 1
- IXGLPNQCLBXUHO-FUHWJXTLSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 IXGLPNQCLBXUHO-FUHWJXTLSA-N 0.000 claims 1
- IWZPVFATWJHPPC-JTHBVZDNSA-N 4-[[7,7-difluoro-5-methyl-6-oxo-9-[(1r,2s)-2-phenylcyclopropyl]-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-n-[3-(dimethylamino)propyl]-3-methoxybenzamide Chemical compound COC1=CC(C(=O)NCCCN(C)C)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2[C@H]3[C@@H](C3)C=3C=CC=CC=3)C2=N1 IWZPVFATWJHPPC-JTHBVZDNSA-N 0.000 claims 1
- GLTMSDBAMFENHK-UHFFFAOYSA-N 4-[[7,7-difluoro-9-[(4-methoxyphenyl)methyl]-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl]amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1=CC(OC)=CC=C1CN1C2=NC(NC=3C(=CC(=CC=3)C(=O)NC3CCN(C)CC3)OC)=NC=C2N(C)C(=O)C(F)(F)C1 GLTMSDBAMFENHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (3)
- 式I:
式中
R1が−(CH2)n−アリール(アリールはフェニル及びチオフェニルからなる群より選択される)、またはフェニルシクロプロピルであり;
R2が水素、メチル、エチルまたはプロピルであり;
R3、R3’、およびR3’’がそれぞれ独立して水素、クロロ、フルオロ、C1〜C5直鎖もしくは分鎖アルキル、トリフルオロメチル、メトキシ、エトキシ、トリフルオロメトキシ、またはトリフルオロエトキシであり;
R4が、ヒドロキシル、アミノ、メトキシ、R5−NH−、または
式中Xが、CH2、O、またはNHであり、XがCH2またはNHである場合、Xは任意にアミノまたはC1〜C5直鎖もしくは分鎖アルキルにより置換されてよく;
R5が
nが0〜4の整数であり、
R7が水素、またはC1〜C5直鎖もしくは分鎖アルキルであり、
R13がR14R15N−であり、
R14とR15が独立して水素、C1〜C5直鎖もしくは分鎖アルキル、C3〜C6シクロアルキル、またはフェニルである化合物
またはその製薬上許容可能な塩。 - 以下からなる群から選択される請求項1に記載の化合物:
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−安息香酸;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(1−メチル−ピペリジン−4−イル)−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−メチル−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−N−(3−ジメチルアミノ−プロピル)−3−メトキシ−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(2−チオフェン−2−イル−エチル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(テトラヒドロ−ピラン−4−イル)−ベンズアミド;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−3−メトキシ−安息香酸;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−3−メトキシ−N−(1−メチル−ピペリジン−4−イル)−ベンズアミド;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−3−メトキシ−ベンズアミド;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−3−メトキシ−N−メチル−ベンズアミド;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−N−(3−ジメチルアミノ−プロピル)−3−メトキシ−ベンズアミド;
4−(7,7−ジフルオロ−5−メチル−6−オキソ−9−フェネチル−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ)−3−メトキシ−N−(テトラヒドロ−ピラン−4−イル)−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−安息香酸;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(1−メチル−ピペリジン−4−イル)−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−メチル−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−N−(3−ジメチルアミノ−プロピル)−3−メトキシ−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(3−フェニル−プロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(テトラヒドロ−ピラン−4−イル)−ベンズアミド;及び
4−[7,7−ジフルオロ−9−(4−メトキシ−ベンジル)−5−メチル−6−オキソ−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(1−メチル−ピペリジン−4−イル)−ベンズアミド;
または上記化合物の製薬上許容される塩。 - 以下からなる群から選択される請求項1に記載の化合物:
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(トランス−2−フェニル−シクロプロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−安息香酸;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(トランス−2−フェニル−シクロプロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−N−(1−メチル−ピペリジン−4−イル)−ベンズアミド;
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(トランス−2−フェニル−シクロプロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−3−メトキシ−ベンズアミド;及び
4−[7,7−ジフルオロ−5−メチル−6−オキソ−9−(トランス−2−フェニル−シクロプロピル)−6,7,8,9−テトラヒドロ−5H−ピリミド[4,5−b][1,4]ジアゼピン−2−イルアミノ]−N−(3−ジメチルアミノ−プロピル)−3−メトキシ−ベンズアミド;
または上記化合物の製薬上許容される塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7338808P | 2008-06-18 | 2008-06-18 | |
US61/073,388 | 2008-06-18 | ||
PCT/EP2009/057144 WO2009153197A1 (en) | 2008-06-18 | 2009-06-10 | Halo-substituted pyrimidodiazepines as plkl inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011527667A JP2011527667A (ja) | 2011-11-04 |
JP2011527667A5 true JP2011527667A5 (ja) | 2012-08-02 |
Family
ID=41431858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011513994A Abandoned JP2011527667A (ja) | 2008-06-18 | 2009-06-10 | ハロ置換ピリミドジアゼピン |
Country Status (4)
Country | Link |
---|---|
US (1) | US8003785B2 (ja) |
EP (1) | EP2303889A1 (ja) |
JP (1) | JP2011527667A (ja) |
WO (1) | WO2009153197A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ584760A (en) | 2007-09-25 | 2012-03-30 | Takeda Pharmaceutical | Polo-like kinase inhibitors |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
RU2012116526A (ru) | 2009-09-25 | 2013-10-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
CN102548994A (zh) * | 2009-09-25 | 2012-07-04 | 沃泰克斯药物股份有限公司 | 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法 |
CA2812683C (en) | 2009-09-25 | 2017-10-10 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011042217A1 (en) | 2009-10-09 | 2011-04-14 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
JP5504898B2 (ja) * | 2010-01-08 | 2014-05-28 | セントラル硝子株式会社 | ジフルオロシクロプロパン化合物の製造方法 |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
CN102947265B (zh) | 2010-04-19 | 2015-07-29 | 奥瑞泽恩基因组学股份有限公司 | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 |
WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
EP3981395A1 (en) | 2011-02-08 | 2022-04-13 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
US10150756B2 (en) | 2014-01-31 | 2018-12-11 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
CA2955074A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
CN105646398B (zh) * | 2014-12-05 | 2018-09-07 | 上海医药工业研究院 | N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法 |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS |
MX2018003030A (es) | 2015-09-11 | 2018-04-11 | Dana Farber Cancer Inst Inc | Acetamida tienotriazolodiazepinas y usos de las mismas. |
RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
KR102337029B1 (ko) | 2020-03-27 | 2021-12-09 | (주) 업테라 | Plk1 선택적 분해 유도 화합물 |
WO2022145989A1 (ko) * | 2020-12-31 | 2022-07-07 | (주) 업테라 | 선택적 plk1 억제제로서의 피리미도디아제핀 유도체 |
JP2023540728A (ja) * | 2021-08-10 | 2023-09-26 | オップテラ インコーポレイテッド | 新規plk1分解誘導化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1268481B1 (en) | 1999-09-17 | 2007-12-12 | Abbott GmbH & Co. KG | Kinase inhibitors as therapeutic agents |
DE50207522D1 (de) | 2001-09-04 | 2006-08-24 | Boehringer Ingelheim Int | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
EP1983987B1 (en) | 2006-02-14 | 2010-09-01 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
PL2139892T3 (pl) * | 2007-03-22 | 2012-03-30 | Takeda Pharmaceuticals Co | Podstawione pirymidynodiazepiny użyteczne jako inhibitory plk1 |
NZ584760A (en) | 2007-09-25 | 2012-03-30 | Takeda Pharmaceutical | Polo-like kinase inhibitors |
-
2009
- 2009-06-10 JP JP2011513994A patent/JP2011527667A/ja not_active Abandoned
- 2009-06-10 WO PCT/EP2009/057144 patent/WO2009153197A1/en active Application Filing
- 2009-06-10 EP EP09765777A patent/EP2303889A1/en not_active Withdrawn
- 2009-06-16 US US12/485,108 patent/US8003785B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011527667A5 (ja) | ||
RU2018131134A (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ | |
JP2010521514A5 (ja) | ||
JP2011519854A5 (ja) | ||
JP2019104748A5 (ja) | ||
JP2013537203A5 (ja) | ||
JP2011528658A5 (ja) | ||
JP2008530099A5 (ja) | ||
JP2013519684A5 (ja) | ||
JP2017504635A5 (ja) | ||
RU2009142434A (ru) | Производные триазолопиридин-карбоксамидов и триазолопиримидин-карбоксамидов, их получение и их применение в терапии | |
JP2014521625A5 (ja) | ||
JP2012508252A5 (ja) | ||
HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
JP2011513305A5 (ja) | ||
RU2009142431A (ru) | Производные триазолопиридинкарбоксамидов и триазолопиримидинкарбоксамидов, их получение и их применение в терапии | |
JP2012502067A5 (ja) | ||
JP2010155827A5 (ja) | ||
JP2013542218A5 (ja) | ||
JP2012531433A5 (ja) | ||
JP2009516727A5 (ja) | ||
JP2010533203A5 (ja) | ||
JP2010518153A5 (ja) | ||
JP2012516355A5 (ja) | ||
JP2013510178A5 (ja) |